Actively Recruiting
Phase 3 Randomized Study Evaluating KarXTs Effectiveness and Safety in Acutely Psychotic Japanese Adults With Schizophrenia Including a 5-Week Double-Blind and 52-Week Open-Label Extension
Led by Bristol-Myers Squibb · Updated on 2026-11-02
250
Participants Needed
56
Research Sites
47 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of KarXT in adult Japanese participants who are experiencing acute psychotic episodes of schizophrenia. This Phase 3 randomized study focuses on adults aged 18 to 65 with a confirmed diagnosis of schizophrenia based on DSM-5 criteria. The study aims to better understand how KarXT affects symptoms and overall severity of schizophrenia. Participants are assigned to receive either KarXT or a placebo in a double-blind, placebo-controlled manner for 5 weeks. After this period, a 52-week open-label extension allows all participants to receive KarXT to further assess long-term safety and effectiveness. Dosing follows specified schedules, and the study monitors changes in symptoms and adverse events throughout both phases. During the trial, participants will have regular assessments including symptom rating scales like the Positive and Negative Syndrome Scale PANSS and Clinical Global Impressions-Severity CGI-S. Safety evaluations include monitoring adverse events, physical exams, vital signs, laboratory tests, ECGs, and assessments for side effects such as movement disorders and suicidal ideation. The total study duration may extend up to about one year, including both the initial double-blind and the extension phases.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here